

**Series 10**  
**May 2020**

## Department of Pharmacology New drug update



**A PASSION FOR  
BETTER MEDICINE**

Compiled & Edited by  
Department of  
Pharmacology,  
KMCHHSR,  
Coimbatore,  
641014.

Kindly Mail Your  
Suggestions To:  
[hodpharmacology@  
kmchihsr.edu.in](mailto:hodpharmacology@kmchihsr.edu.in)

Access this series through the KMCH  
website [www.kmchihsr.edu.in](http://www.kmchihsr.edu.in)

### Inside the series

- ❖ **Sacituzumab-govitecan-hziy**
- ❖ **Coagulation factor VIIa  
recombinant-jncw**
- ❖ **Selumetinib**
- ❖ **Tucatinib**
- ❖ **Opicapone**
- ❖ **Pemigatinib**
- ❖ **Ephedrine sulphate (premixed  
formulation)**
- ❖ **Mitomycin(pyelocalyceal  
solution)**

**Sacituzumab-govitecan-hziy**  
Approval date – April 22, 2020

<b>Mechanism of action</b>	Trop-2-directed antibody and topoisomerase inhibitor conjugate
<b>Indication</b>	Previously-treated metastatic Triple-Negative Breast Cancer (mTNBC)
<b>Dosage formulation</b>	IV infusion (as Lyophilized powder for reconstitution)

**Selumetinib**  
Approval date – April 10, 2020

<b>Mechanism of action</b>	A mitogen activated protein kinases1&2(MEK1/2)inhibitor
<b>Indication</b>	Paediatric patients aged 2 years & older with symptomatic inoperable Neurofibromatosis 1(NF1)
<b>Dosage formulation</b>	Capsule

**Opicapone**  
Approval date – April 24, 2020

<b>Mechanism of action</b>	A catechol O methyl transferase(COMT) inhibitor
<b>Indication</b>	Parkinsons disease patients with 'off' episodes as an adjunct to levodopa/ carbidopa
<b>Dosage formulation</b>	Capsule

**Ephedrine sulphate**  
Approval date – April 17, 2020

<b>Mechanism of action</b>	Alpha and beta adrenergic agonist and a norepinephrine releasing agent
<b>Indication</b>	Clinically important Hypotension occurring in the setting of anaesthesia.
<b>Dosage formulation</b>	I.V. injection (available as a premixed formulation)

**Coagulation factor VIIa recombinant-jncw**  
Approval date – April 1, 2020

<b>Mechanism of action</b>	Coagulation factor VIIa concentrate
<b>Indication</b>	Patients aged 12 years and older with Hemophilia A or B with inhibitors
<b>Dosage formulation</b>	IV injection (as Lyophilized powder for reconstitution)

**Tucatinib**  
Approval date – April 17, 2020

<b>Mechanism of action</b>	A kinase inhibitor
<b>Indication</b>	Patients with advanced metastatic HER2 +ve Breast carcinoma along with trastuzumab &capecitabine
<b>Dosage formulation</b>	Tablet

**Pemigatinib**  
Approval date – April 17, 2020

<b>Mechanism of action</b>	A fibroblast growth factor receptor(FGFR)inhibitor
<b>Indication</b>	Adults with unresectable locally advanced /metastatic Cholangiocarcinoma
<b>Dosage formulation</b>	Tablet

**Mitomycin**  
Approval date – April 15, 2020

<b>Mechanism of action</b>	An alkylating agent
<b>Indication</b>	Adult patients with Low grade upper tract Urothelial cancer (LG-UTUC)
<b>Dosage formulation</b>	Solution (Pyelocalyceal administration)